The biggest company on London’s stock market, AstraZeneca, set out bold plans today for what it’s boss called “a new era of growth,” powered by 20 new drugs.
The Cambridge-based pharma giant has set a target of $80 billion revenue by 2030, and operating profits around $30 billion.
